Perforin-IN-2

Cat. No.:	HY-160214
CAS No.:	1567836-70-7
Molecular Formula:	$C_{24}H_{18}N_4O_5S_2$
Molecular Weight:	506.55
Target:	Others
Pathway:	Others

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 33.33 mg/mL (65.80 mM; ultrasonic and warming and heat to 80°C)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.9741 mL	9.8707 mL	19.7414 mL
5 mM	0.3948 mL	1.9741 mL	3.9483 mL
10 mM	0.1974 mL	0.9871 mL	1.9741 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: 2.5 mg/mL (4.94 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Perforin-IN-2 is a benzosulfonamide perforin inhibitor that alleviates transplant rejection during allogeneic bone marrow/stem cell transplantation. Perforin-IN-2 binds to plasma proteins with a binding rate of 99.8%. Perforin-IN-2 requires a higher concentration (> 900 μM) to achieve optimal perforin inhibition in vivo. Perforin-in-2 can effectively inhibit the lytic activity of recombinant perforin on Jurkat T (IC_{50}=6.65 μM) leukemia cells, and also inhibit the death of K562 leukemia target cells[1].

REFERENCES

[1]. Gartlan KH, et al. Preclinical Activity and Pharmacokinetic/Pharmacodynamic Relationship for a Series of Novel Benzenesulfonamide Perforin Inhibitors. ACS Pharmacol Transl Sci. 2022 May 31;5(6):429-439.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA